The Analytic and Translational Genetics Unit at Massachusetts General Hospital focuses on the interpretation of genome data to drive progress in understanding and treating human disease.
The Analytic and Translational Genetics Unit is a new Unit within the Department of Medicine. Our overall mission is to focus on the interpretation of individual genome sequence data for both the discovery of the genetic underpinnings of human disease and for the development of paradigms by which individuals' genome sequence can be effectively integrated into clinical decision making. The Unit has a near term efforts in large-scale medical resequencing studies in human disease and pharmacogenetic response and will develop partnerships across the hospital to both identify new opportunities for the use of genetics in the clinic and to address the challenges of the rapidly approaching time when complete genome sequence is available to individual patients.
Mark J. Daly, PhD, the first Chief of the Analytic and Translational Genetics Unit, is an Associate Professor at HMS and a Senior Associate Member of the Broad Institute, where he is Co-Director of Medical and Population Genetics. His laboratory focuses on computational approaches to understanding the genetics of disease and is specifically focused two major areas – extending insights gained from the many genes discovered in Crohn’s and UC to pursue the functional and clinical ramifications thereof and extending genetic studies to include thorough processing and analysis of next-generation sequencing in order to apply it to autism, ADHD and other psychiatric diseases as well as rare Mendelian diseases.
Discover the largest hospital-based research program in the U.S. and how clinicians and scientists chart new terrain in biomedical research to treat and prevent human disease and bring the latest advances to patient care
U.S. News & World Report ranks Mass General the #1 hospital in America based on our quality of care, patient safety and reputation in 16 different specialties. Learn more about why we're #1.